Continuous perfusion with interleukin 6 (IL-6) enhances production of hematopoietic stem cells (CFU-S).
The in vivo effect of human recombinant IL-6 on hematopoietic stem cells (colony forming units in spleen, CFU-S) was investigated. Normal mice perfused with IL-6 for 7 days showed an increase in the serum level of IL-6 in a dose-dependent manner. This increase was accompanied by a dramatic enhancement (approximately 8-fold) in the number of spleen CFU-S 7 days after starting perfusion, although heat-treated IL-6 did not exhibit any activities. Enhanced CFU-S number returned to normal at 13 days after cessation of perfusion. These results suggest that IL-6 could be valuable for treating various forms of hematopoietic depletion.
Suzuki
C
C
Central Research Laboratories, Ajinomoto Co., Inc., Kawasaki, Japan.
Okano
A
A
Takatsuki
F
F
Miyasaka
Y
Y
Hirano
T
T
Kishimoto
T
T
Ejima
D
D
Akiyama
Y
Y
D000818:Animals; D005260:Female; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects; D015850:Interleukin-6; D007378:Interleukins / Q000097:blood / Q000494:pharmacology*; D008264:Macrophages / Q000166:cytology / Q000187:drug effects; D051379:Mice; D008809:Mice, Inbred C3H; D008811:Mice, Inbred DBA; D010477:Perfusion; D011994:Recombinant Proteins / Q000494:pharmacology; D012016:Reference Values
D015850:Interleukin-6; D007378:Interleukins; D011994:Recombinant Proteins